Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immuron Limited ( (AU:IMC) ) just unveiled an update.
Immuron Limited announced several key updates, including the anticipated topline results of the Travelan® clinical study and the submission of an IND application for IMM-529 to the FDA. The company is on track for the commercial launch of ProIBS® in Australia by Q4 2025, with a full launch expected in Q1 2026. Immuron’s progress in these areas highlights its strategic focus on expanding its product offerings and strengthening its market position in the treatment of gastrointestinal and infectious diseases.
More about Immuron Limited
Immuron Limited operates in the pharmaceutical industry, focusing on the development and commercialization of oral immunotherapeutic products. Its primary products include Travelan® for traveler’s diarrhea, IMM-529 for Clostridioides difficile infection, and ProIBS® for irritable bowel syndrome. The company is also engaged in pre-clinical research for IMM-986 targeting Vancomycin-resistant Enterococci.
Average Trading Volume: 204,298
Technical Sentiment Signal: Sell
Current Market Cap: A$20.38M
For detailed information about IMC stock, go to TipRanks’ Stock Analysis page.